GlassScriptPhysician profile
Anil K Puri
NPI 1629166335
$3,880.09
in general payments reported to CMS, 2019-2025
27 companies · $33.95 in 2025
The $33.95 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $517 · 2021: $842 · 2022: $1,018 · 2023: $595 · 2024: $253 · 2025: $33.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,113.08 | 2019-2023 | Symbicort, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $533.66 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $259.47 | 2019-2023 | Ozempic, Rybelsus |
| Genzyme Corporation | $195.98 | 2019-2025 | |
| Pfizer INC. | $187.53 | 2019-2022 | |
| Lilly USA, LLC | $161.37 | 2020-2023 | Mounjaro |
| Edwards Lifesciences Corporation | $150.44 | 2024 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $126.15 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $115.72 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $111.73 | 2021-2022 | |
| Harmony Biosciences LLC | $108.85 | 2020-2023 | Wakix |
| Abbott Laboratories | $94.63 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $93.89 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $93.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.82 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $68.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.49 | 2023 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $57.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $47.23 | 2019-2022 | |
| Mylan Specialty L.P. | $45.04 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $38.72 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $37.82 | 2019-2022 | |
| Baxter Healthcare | $23.20 | 2022 | |
| Philips North America LLC | $22.60 | 2019 | |
| Resmed Corp | $22.12 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.04 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.